Novartis AG
Antibody molecules to PD-L1 and methods of treating cancer

Last updated:

Abstract:

Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Status:
Grant
Type:

Utility

Filling date:

20 Feb 2018

Issue date:

1 Dec 2020